+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
DNA Repair Drugs Market - Global Forecast 2026-2032- Product Image
DNA Repair Drugs Market - Global Forecast 2026-2032- Product Image
New

DNA Repair Drugs Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 182 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5977983
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The DNA Repair Drugs Market stands at a pivotal juncture, marked by rapid advances in therapeutic modalities, changing regulatory requirements, and evolving clinical priorities. In this environment, decision-makers need actionable insights to navigate both scientific and operational complexities and achieve sustainable commercial growth.

Market Snapshot: DNA Repair Drugs Market Growth and Outlook

The DNA Repair Drugs Market expanded from USD 9.87 billion in 2025 to USD 10.53 billion in 2026 and is forecasted to reach USD 16.31 billion by 2032, reflecting a CAGR of 7.43%. This growth is driven by the maturation of DNA repair science from foundational research to applied clinical therapeutics, with targeted interventions addressing cancer and genetic disorders. The evolving clinical landscape and competitive pressure are reinforcing the importance of robust evidence generation and cross-functional collaboration across the sector.

Scope & Segmentation of the DNA Repair Drugs Market

  • Drug Classes: Atm inhibitors, Atr inhibitors, DNA methyltransferase inhibitors, Hdac inhibitors, Parp inhibitors, monoclonal antibodies, peptides, and small molecules are actively shaping product pipelines and development strategies.
  • Mechanism of Action: Modalities include direct DNA repair modulation and adjunctive or targeting roles, with special attention to biomarker-driven and companion diagnostic innovation.
  • Clinical Indications: Key focus areas encompass breast (Her2 positive, hormone receptor positive, triple negative), ovarian, pancreatic, and prostate cancers, each with unique unmet needs and evidentiary requirements.
  • Route of Administration: Choices span intravenous, oral, and subcutaneous formulations, influencing patient adherence, care planning, and distribution.
  • End-User Dynamics: Strategic access points include hospitals, pharmacies, and specialty clinics, each dictating tailored commercialization pathways and reimbursement strategies.
  • Regions: Comprehensive analysis covers Americas, Europe, Middle East & Africa, and Asia-Pacific, accounting for distinct regulatory, clinical, manufacturing, and commercial environments.

Key Takeaways for Decision-Makers

  • Scientific innovations in DNA damage response have moved the market from early discovery to targeted, biomarker-enriched therapeutic solutions that align with clinical and payer expectations.
  • Biomarker strategy and companion diagnostic integration are now central to trial design, product differentiation, and real-world evidence generation.
  • Supply chain resilience and agile manufacturing have become major factors in candidate selection, site geography, and commercial execution amid global policy and trade shifts.
  • Segmentation by drug class and mechanism of action impacts both clinical development paths and regulatory discussions, shaping future product access.
  • Strategic partnerships—including co-development, licensing, and supply agreements—define the competitive landscape and accelerate progress through clinical milestones.
  • Regional nuance requires tailored planning for regulatory approval, launch sequencing, and reimbursement, particularly where diagnostic infrastructure and payer systems vary.

Tariff Impact on Supply Chains and Strategy

Recent United States tariff measures introduced in 2025 have altered the production economics for DNA repair drug developers by raising import costs of raw materials and active ingredients. To mitigate downstream risks, companies are now diversifying supply chains, investing in regional manufacturing, and qualifying alternative suppliers. Regulatory pathways must adapt as changes in supplier sources require extra validation and documentation, which can lengthen timelines. Commercial teams are responding with value-based agreements and reinforced multi-stakeholder engagement to manage cost pressures and access challenges.

Methodology & Data Sources

This report is built upon comprehensive primary research, including expert interviews with clinical, regulatory, commercial, and manufacturing leaders. Findings were validated through triangulation with secondary sources, such as peer-reviewed literature, regulatory guidance, and company disclosures. Quality assurance measures ensure methodological rigor, transparency, and actionable conclusions.

Why This Report Matters

  • Provides senior leadership with evidence-based guidance on scientific, regulatory, and commercial drivers of value within the DNA repair drugs market.
  • Enables informed investment and strategy formulation for pipeline prioritization, partnership, and risk management across global regions.
  • Positions organizations to proactively address evolving payer requirements, operational bottlenecks, and access barriers in a dynamic therapeutic area.

Conclusion

With robust science, evolving regulation, and segmentation shaping access, the DNA Repair Drugs Market demands coordinated strategy and operational agility. Stakeholders who align early and adapt cross-functionally will be best positioned for durable success.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. DNA Repair Drugs Market, by Drug Class
8.1. Atm Inhibitors
8.2. Atr Inhibitors
8.3. Dna Methyltransferase Inhibitors
8.4. Hdac Inhibitors
8.5. Parp Inhibitors
9. DNA Repair Drugs Market, by Mechanism Of Action
9.1. Monoclonal Antibodies
9.2. Peptides
9.3. Small Molecules
10. DNA Repair Drugs Market, by Indication
10.1. Breast Cancer
10.1.1. Her2 Positive
10.1.2. Hormone Receptor Positive
10.1.3. Triple Negative
10.2. Ovarian Cancer
10.3. Pancreatic Cancer
10.4. Prostate Cancer
11. DNA Repair Drugs Market, by Route Of Administration
11.1. Intravenous
11.2. Oral
11.3. Subcutaneous
12. DNA Repair Drugs Market, by End User
12.1. Hospitals
12.2. Pharmacies
12.3. Specialty Clinics
13. DNA Repair Drugs Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. DNA Repair Drugs Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. DNA Repair Drugs Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States DNA Repair Drugs Market
17. China DNA Repair Drugs Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. Artios Pharma
18.6. AstraZeneca PLC
18.7. Aurigene Discovery Technologies
18.8. Bio-Rad Laboratories, Inc.
18.9. Bristol-Myers Squibb Company
18.10. CanBas Co., Ltd.
18.11. Clovis Oncology
18.12. Corden Pharma International GmbH
18.13. Eli Lilly and Company
18.14. Genentech, Inc.
18.15. GlaxoSmithKline PLC
18.16. Hanson Wade Group
18.17. Johnson & Johnson Services, Inc.
18.18. Merck KgaA
18.19. Novartis AG
18.20. Pfizer Inc.
18.21. Valerio Therapeutics
List of Figures
FIGURE 1. GLOBAL DNA REPAIR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL DNA REPAIR DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL DNA REPAIR DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA DNA REPAIR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL DNA REPAIR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATM INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATM INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATM INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATR INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATR INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATR INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HDAC INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HDAC INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HDAC INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HER2 POSITIVE, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HER2 POSITIVE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HER2 POSITIVE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY TRIPLE NEGATIVE, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY TRIPLE NEGATIVE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY TRIPLE NEGATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY OVARIAN CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY OVARIAN CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PANCREATIC CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PANCREATIC CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 73. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 74. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 75. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 76. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 77. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 78. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 79. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 81. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 82. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 83. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 84. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 85. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 86. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 88. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 89. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 90. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 91. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 92. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 100. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 101. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 102. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 103. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 104. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 105. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 106. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 107. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 108. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 109. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 110. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 111. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 112. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 113. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 114. AFRICA DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 115. AFRICA DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 116. AFRICA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 117. AFRICA DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 118. AFRICA DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 119. AFRICA DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 120. AFRICA DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 121. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 122. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 123. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 124. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 125. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 126. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 127. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 129. ASEAN DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 130. ASEAN DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 131. ASEAN DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 132. ASEAN DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 133. ASEAN DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 134. ASEAN DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 135. ASEAN DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 136. GCC DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 137. GCC DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 138. GCC DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 139. GCC DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 140. GCC DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 141. GCC DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 142. GCC DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 143. EUROPEAN UNION DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 144. EUROPEAN UNION DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 145. EUROPEAN UNION DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 146. EUROPEAN UNION DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 147. EUROPEAN UNION DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 148. EUROPEAN UNION DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 149. EUROPEAN UNION DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 150. BRICS DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 151. BRICS DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 152. BRICS DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 153. BRICS DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 154. BRICS DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 155. BRICS DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 156. BRICS DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 157. G7 DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 158. G7 DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 159. G7 DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 160. G7 DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 161. G7 DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 162. G7 DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 163. G7 DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 164. NATO DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 165. NATO DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 166. NATO DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 167. NATO DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 168. NATO DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 169. NATO DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 170. NATO DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 171. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 172. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 173. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 174. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 175. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 176. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 177. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 178. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 179. CHINA DNA REPAIR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 180. CHINA DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 181. CHINA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 182. CHINA DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 183. CHINA DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 184. CHINA DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 185. CHINA DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this DNA Repair Drugs market report include:
  • Artios Pharma
  • AstraZeneca PLC
  • Aurigene Discovery Technologies
  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb Company
  • CanBas Co., Ltd.
  • Clovis Oncology
  • Corden Pharma International GmbH
  • Eli Lilly and Company
  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Hanson Wade Group
  • Johnson & Johnson Services, Inc.
  • Merck KgaA
  • Novartis AG
  • Pfizer Inc.
  • Valerio Therapeutics

Table Information

Report AttributeDetails
No. of Pages182
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 10.53 Billion
Forecasted Market Value ( USD ) by 2032 $ 16.31 Billion
Compound Annual Growth Rate7.4%
Regions CoveredGlobal
No. of Companies Mentioned18

Related Topics

Related Reports

DNA Repair Drugs - Global Strategic Business Report - Product Image

DNA Repair Drugs - Global Strategic Business Report

  • Report
  • 217 Pages
  • Global
From
DNA Repair Drugs Market Report 2025 - Product Image

DNA Repair Drugs Market Report 2025

  • Report
  • 250 Pages
  • Global
From
DNA Repair Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

DNA Repair Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Deoxyribonucleic Acid (DNA) Repair Alkylating Agent Market Report 2025 - Product Image

Deoxyribonucleic Acid (DNA) Repair Alkylating Agent Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Epigenetic Regulation of Cancer - Part A. International Review of Cell and Molecular Biology Volume 380 - Product Image

Epigenetic Regulation of Cancer - Part A. International Review of Cell and Molecular Biology Volume 380

  • Book
  • Global

About the DNA Repair Drug Market

The DNA Repair Drug market is a subset of the genomics industry that focuses on the development of drugs that can repair damaged DNA. These drugs are used to treat a variety of genetic diseases, including cancer, and can be used to prevent the onset of certain diseases. DNA repair drugs are typically administered through a variety of methods, including intravenous, oral, and topical applications. The DNA Repair Drug market is highly competitive, with a number of companies vying for market share. Companies in the market include AstraZeneca, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. These companies are actively researching and developing new drugs to treat genetic diseases, as well as exploring new methods of delivery. Additionally, many of these companies are investing in research and development to create more effective treatments for genetic diseases. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.